Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions
Prosthetic Joint Infection
Interventions
DRUG

TRL1068, a human monoclonal antibody

A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

Trial Locations (9)

21215

Sinai Hospital of Baltimore, Baltimore

22903

University of Virginia, Charlottesville

32611

University of Florida, Gainesville

33321

Phoenix Clinical Research, Tamarac

34232

Gulfcoast Research Institute, Sarasota

35205

University of Alabama, Birmingham

77030

Houston Methodist Research Institute, Houston

90033

USC, Los Angeles

90404

UCLA, Santa Monica

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

Biomedical Advanced Research and Development Authority

FED

collaborator

Wellcome Trust

OTHER

collaborator

Sinai Hospital of Baltimore

OTHER

collaborator

Gulfcoast Research Institute

UNKNOWN

collaborator

Phoenix Clinical Research

OTHER

collaborator

University of Florida

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

University of Virginia

OTHER

collaborator

University of Southern California

OTHER

lead

Trellis Bioscience LLC

INDUSTRY